Basal and insulin mediated VLDL-triglyceride kinetics in type 2 diabetic men

Diabetes

Volumn 60, Issue 1, 2011, Pages 88-96

  Sørensen, Lars P ^a   Andersen, Iben R ^a   Søndergaard, Esben ^a   Gormsen, Lars C ^a   Schmitz, Ole ^b   Christiansen, Jens S ^a   Nielsen, Søren ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; CALORIMETRY; CLEARANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; ENERGY EXPENDITURE; FATTY ACID OXIDATION; HUMAN; HYPERINSULINEMIA; KINETICS; LIPID STORAGE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ADIPOSE TISSUE; ADULT; AGED; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; ENERGY INTAKE; FATTY ACIDS; FATTY ACIDS, NONESTERIFIED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; ISOTOPE LABELING; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; REFERENCE VALUES; TRIGLYCERIDES;

EID: 78751528564     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-0564     Document Type: Article

References (31)

1. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260:1917-1921
2. Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Thibult N, Warnet JM, Claude JR, Rosselin GE. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989;32:300-304
3. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85: 37-45
4. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003;46:733-749
5. Adiels M, Olofsson SO, Taskinen MR, Boren J. Diabetic dyslipidaemia. Curr Opin Lipidol 2006;17:238-246
6. Verges B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabete Metab 2005;31:429-439
7. Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 2003;31:1066-1069
8. Ouguerram K, Magot T, Zair Y, Marchini JS, Charbonnel B, Laouenan H, Krempf M. Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes. J Pharmacol Exp Ther 2003;306: 332-337
9. Cummings MH, Watts GF, Umpleby AM, Hennessy TR, Naoumova R, Slavin BM, Thompson GR, Sonksen PH. Increased hepatic secretion of very-lowdensity lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia 1995;38: 959-967
10. Kissebah AH, Alfarsi S, Evans DJ, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes 1982;31:217-225
11. Adiels M, Boren J, Caslake MJ, Stewart P, Soro A, Westerbacka J, Wennberg B, Olofsson SO, Packard C, Taskinen MR. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2005;25:1697-1703
12. Taskinen MR, Packard CJ, Shepherd J. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Diabetes 1990;39:1017-1027
13. Lewis GF, Uffelman KD, Szeto LW, Steiner G. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 1993;42:833-842
14. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 1995;95:158-166
15. Malmström R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Järvinen H, Shepherd J, Taskinen MR. Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes 1998;47: 779-787
16. Malmström R, Packard CJ, Watson TD, Rannikko S, Caslake M, Bedford D, Stewart P, Yki-Järvinen H, Shepherd J, Taskinen MR. Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 1997;17:1454-1464
17. Adiels M, Westerbacka J, Soro-Paavonen A, Hakkinen AM, Vehkavaara S, Caslake MJ, Packard C, Olofsson SO, Yki-Järvinen H, Taskinen MR, Boren J. Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia 2007;50:2356-2365
18. Gormsen LC, Jensen MD, Nielsen S. Measuring VLDL-triglyceride turnover in humans using ex vivo-prepared VLDL tracer. J Lipid Res 2006;47:99-106
19. Sørensen L, Gormsen L, Nielsen S. VLDL-TG kinetics: a dual isotope study for quantifying VLDL-TG pool size, production rates and fractional oxidation in humans. Am J Physiol Endocrinol Metab 2009
20. Jensen MD, Kanaley JA, Reed JE, Sheedy PF. Measurement of abdominal and visceral fat with computed tomography and dual-energy X-ray absorptiometry. Am J Clin Nutr 1995;61:274-278
21. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 1983;55:628-634
22. Marin P, Rebuffe-Scrive M, Bjö rntorp P. Uptake of triglyceride fatty acids in adipose tissue in vivo in man. Eur J Clin Invest 1990;20:158-165
23. Sidossis LS, Coggan AR, Gastaldelli A, Wolfe RR. A new correction factor for use in tracer estimations of plasma fatty acid oxidation. Am J Physiol Endocrinol Metab 1995;269:E649-E656
24. Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol Endocrinol Metab 1984;247:F632-F636
25. Cummings MH, Watts GF, Umpleby AM, Hennessy TR, Kelly JM, Jackson NC, Sonksen PH. Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetes 1995;44:1059-1065
26. Malmström R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Järvinen H, Shepherd J, Taskinen MR. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 1997;40:454-462
27. Gormsen LC, Nellemann B, Sørensen LP, Jensen MD, Christiansen JS, Nielsen S. Impact of body composition on very-low-density lipoproteintriglycerides kinetics. Am J Physiol Endocrinol Metab 2009;296:E165-E173
28. Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 2000;49:677-683
29. Firth R, Bell P, Rizza R. Insulin action in non-insulin-dependent diabetes mellitus: the relationship between hepatic and extrahepatic insulin resistance and obesity. Metabolism 1987;36:1091-1095
30. Magkos F, SidossisLS. Measuring very low density lipoprotein-triglyceride kinetics in man in vivo: how different the various methods really are. Curr Opin Clin Nutr Metab Care 2004;7:547-555
31. Horowitz JF, Klein S. Lipid metabolism during endurance exercise. Am J Clin Nutr 2000;72:558S-563S